Companies: 10,795·Total market cap: $144.5T
Prometheus Biosciences, Inc.

Prometheus Biosciences, Inc.

RXDXNASDAQHealthcare
$199.92
+$0.18(+0.09%)
Market Cap$9.6B
P/E Ratio—
52W High$199.96
52W Low$23.27
SEC Filings

Prometheus Biosciences, Inc. (RXDX) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001718852 · RXDX · NASDAQ · as of Jun 9, 2026

Filing snapshot

189
Total Filings
15-12G
Latest Form
2023-06-27
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001718852 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2023-04-28
Fiscal Year End
Apr 28, 2023
Accession No.
0001193125-23-127124
Primary Document
d478529d10ka.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001718852 · Accession 0001193125-23-127124

Latest Key Filings

10-QQuarterly Report
10-Q
2023-05-09
View 10-Q on SEC
8-KCurrent Report
8-K
2023-06-16Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
15-12G15-12G
FORM 15-12G
2023-06-27
View
25-NSE25-NSE
25-NSE
2023-06-16
View
S-8 POSS-8 POS
S-8 POS
2023-06-16
View
S-8 POSS-8 POS
S-8 POS
2023-06-16
View
POSASRPOSASR
POSASR
2023-06-16
View
8-KCurrent Report
8-K
2023-06-16
View
8-KCurrent Report
8-K
2023-06-15
View
DEFA14AProxy Statement (Additional)
DEFA14A
2023-06-06
View
DEFA14AProxy Statement (Additional)
DEFA14A
2023-05-23
View
8-KCurrent Report
8-K
2023-05-23
View
DEFM14ADEFM14A
DEFM14A
2023-05-16
View
10-QQuarterly Report
10-Q
2023-05-09
View
8-KCurrent Report
8-K
2023-05-09
View
PREM14APREM14A
PREM14A
2023-04-28
View
10-K/AAnnual Report (Amended)
10-K/A
2023-04-28
View
Showing 1–15 of 120 filingsForm 4 / 144 hidden· 189 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001718852  |  Exchange: NASDAQ · Healthcare

Prometheus Biosciences, Inc. (NASDAQ: RXDX) has submitted 189 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001718852, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Prometheus Biosciences, Inc.'s most comprehensive regulatory disclosure. The most recent Prometheus Biosciences, Inc. 10-K was filed on 2023-04-28 for fiscal year ending 2023. Historical RXDX 10-K annual reports are available from 2017 through 2023.

Investors researching Prometheus Biosciences, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-09
Related Companies SEC Filings — Healthcare
ROIV SEC Filings →KRTX SEC Filings →WBA SEC Filings →OSH SEC Filings →SGFY SEC Filings →IMGN SEC Filings →BPMC SEC Filings →CERE SEC Filings →
→ RXDX Financials→ RXDX Earnings→ RXDX Insider Trades

Frequently Asked Questions

RXDX SEC Filings · 8 questions

Prometheus Biosciences, Inc. (RXDX) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 189 filings and access original documents at no cost. Prometheus Biosciences, Inc.'s CIK is 0001718852.

RXDX SEC filingsPrometheus Biosciences, Inc. SEC documentsfind RXDX 10-K